OncoMatch/Clinical Trials/NCT07333261

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

Is NCT07333261 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BMS-986453 for multiple myeloma.

Phase 1RecruitingSusan BalNCT07333261Data as of May 2026

Treatment: BMS-986453 — This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.

Check if I qualify

Extracted eligibility criteria

Cancer type

Multiple Myeloma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of Alabama at Birmingham · Birmingham, Alabama

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify